Literature DB >> 14688410

Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression.

Sung-Hee Chang1, Catherine H Liu, Rebecca Conway, David K Han, Kasem Nithipatikom, Ovidiu C Trifan, Timothy F Lane, Timothy Hla.   

Abstract

Overexpression of human cyclooxygenase 2 (COX-2) in the mammary glands of transgenic mice induces tissue-specific tumorigenic transformation. However, the molecular mechanisms involved are not yet defined. Here we show that COX-2 expressed in the epithelial cell compartment regulates angiogenesis in the stromal tissues of the mammary gland. Microvessel density increased before visible tumor growth and exponentially during tumor progression. Inhibition of prostanoid synthesis with indomethacin strongly decreased microvessel density and inhibited tumor progression. Up-regulation of angiogenic regulatory genes in COX-2 transgenic mammary tissue was also potently inhibited by indomethacin treatment, suggesting that prostanoids released from COX-2-expressing mammary epithelial cells induce angiogenesis. G protein-coupled receptors for the major product, prostaglandin E(2) (PGE(2)) EP(1-4), are expressed during mammary gland development, and EP(1,2,4) receptors were up-regulated in tumor tissue. PGE(2) stimulated the expression angiogenic regulatory genes in mammary tumor cells isolated from COX-2 transgenic mice. Such cells are tumorigenic in nude mice; however, treatment with Celecoxib, a COX-2-specific inhibitor, reduced tumor growth and microvessel density. These results define COX-2-derived PGE(2) as a potent inducer of angiogenic switch during mammary cancer progression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14688410      PMCID: PMC327192          DOI: 10.1073/pnas.2535911100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma.

Authors:  Harold F Dvorak
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

2.  Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps.

Authors:  Hiroshi Seno; Masanobu Oshima; Tomo-o Ishikawa; Hiroko Oshima; Kazuaki Takaku; Tsutomu Chiba; Shuh Narumiya; Makoto M Taketo
Journal:  Cancer Res       Date:  2002-01-15       Impact factor: 12.701

Review 3.  Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.

Authors:  R A Gupta; R N Dubois
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

4.  Selective cyclooxygenase-1 and -2 inhibitors each increase allergic inflammation and airway hyperresponsiveness in mice.

Authors:  R Stokes Peebles; Koichi Hashimoto; Jason D Morrow; Ryszard Dworski; Robert D Collins; Yuko Hashimoto; John W Christman; Kyung-Ho Kang; Kasia Jarzecka; Jamye Furlong; Daphne B Mitchell; Megha Talati; Barney S Graham; James R Sheller
Journal:  Am J Respir Crit Care Med       Date:  2002-04-15       Impact factor: 21.405

5.  Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice.

Authors:  M Sonoshita; K Takaku; N Sasaki; Y Sugimoto; F Ushikubi; S Narumiya; M Oshima; M M Taketo
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

6.  Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors.

Authors:  Shunichi Morikawa; Peter Baluk; Toshiyuki Kaidoh; Amy Haskell; Rakesh K Jain; Donald M McDonald
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

7.  Liquid chromatographic-mass spectrometric determination of cyclooxygenase metabolites of arachidonic acid in cultured cells.

Authors:  Kasem Nithipatikom; Nathan D Laabs; Marilyn A Isbell; William B Campbell
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-02-25       Impact factor: 3.205

8.  Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis.

Authors:  Karin Muller-Decker; Gitta Neufang; Irina Berger; Melanie Neumann; Friedrich Marks; Gerhard Furstenberger
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-09       Impact factor: 11.205

9.  Prostaglandin E2 regulates aromatase activity and expression in human adipose stromal cells via two distinct receptor subtypes.

Authors:  Jeanette A Richards; Robert W Brueggemeier
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

10.  Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.

Authors:  Louise R Howe; Kotha Subbaramaiah; Jay Patel; Jaime L Masferrer; Aparna Deora; Clifford Hudis; Howard T Thaler; William J Muller; Baoheng Du; Anthony M C Brown; Andrew J Dannenberg
Journal:  Cancer Res       Date:  2002-10-01       Impact factor: 12.701

View more
  130 in total

1.  Mechanisms Mediating the Synergistic Anticancer Effects of Combined γ-Tocotrienol and Celecoxib Treatment.

Authors:  Amit B Shirode; Paul W Sylvester
Journal:  J Bioanal Biomed       Date:  2011-01-10

2.  Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch.

Authors:  Dingzhi Wang; Raymond N DuBois
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-05       Impact factor: 11.205

Review 3.  Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers.

Authors:  Sarah C Baumgarten; Jonna Frasor
Journal:  Mol Endocrinol       Date:  2012-02-02

Review 4.  Integrin α3β1 as a breast cancer target.

Authors:  Sita Subbaram; C Michael Dipersio
Journal:  Expert Opin Ther Targets       Date:  2011-08-13       Impact factor: 6.902

Review 5.  Prostaglandins and cancer.

Authors:  D Wang; R N Dubois
Journal:  Gut       Date:  2005-08-23       Impact factor: 23.059

6.  Non-steroidal anti-inflammatory drug use, hormone receptor status, and breast cancer-specific mortality in the Carolina Breast Cancer Study.

Authors:  E H Allott; C-K Tse; A F Olshan; L A Carey; P G Moorman; M A Troester
Journal:  Breast Cancer Res Treat       Date:  2014-08-24       Impact factor: 4.872

7.  15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers.

Authors:  Min Yan; Ronald M Rerko; Petra Platzer; Dawn Dawson; Joseph Willis; Min Tong; Earl Lawrence; James Lutterbaugh; Shilong Lu; James K V Willson; Guangbin Luo; Jack Hensold; Hsin-Hsiung Tai; Keith Wilson; Sanford D Markowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-01       Impact factor: 11.205

8.  Celecoxib enhances the efficacy of 15-hydroxyprostaglandin dehydrogenase gene therapy in treating murine breast cancer.

Authors:  Binglan Zhang; Xuelei Ma; Zhimian Li; Xiang Gao; Fengtian Wang; Lei Liu; Guobo Shen; Yaxiong Sang; Minmin Li; Yuli Li; Jingyi Zhao; Yuquan Wei
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-06       Impact factor: 4.553

9.  Essential role of sphingosine 1-phosphate receptor 2 in pathological angiogenesis of the mouse retina.

Authors:  Athanasia Skoura; Teresa Sanchez; Kevin Claffey; Suzanne M Mandala; Richard L Proia; Timothy Hla
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

10.  The malignant phenotype of breast cancer cells is reduced by COX-2 silencing.

Authors:  Ioannis Stasinopoulos; Noriko Mori; Zaver M Bhujwalla
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.